Abstract Details

Title Analysis of Psychiatric Treatment-Emergent Adverse Events (TEAEs) in Two Phase III Conversion-to-Eslicarbazepine Acetate (ESL) Monotherapy Trials

Topic Epilepsy/Clinical Neurophysiology (EEG)

Presentation(s) P5 - (-)

Poster/Presentation
Number 270

Background

Objective

Design/Methods

Results

Conclusions

Authors/Disclosures
Cynthia L. Harden, MD (Xenon Pharmaceuticals Inc) PRESENTER	Dr. Harden has received personal compensation for serving as an employee of Xenon Pharmaceuticals Inc.. Dr. Harden has stock in Xenon Pharmaceuticals Inc.. Dr. Harden has received intellectual property interests from a discovery or technology relating to health care.
Jay Salpekar	No disclosure on file
David W. Loring, PhD, FAAN (Emory Univ, Dept of Neurology)	Dr. Loring has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. Dr. Loring has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for ILAE. The institution of Dr. Loring has received research support from NIH. Dr. Loring has received publishing royalties from a publication relating to health care.
Todd Grinnell, PhD	Todd Grinnell, PhD has received personal compensation for serving as an employee of Sunovion Pharmaceuticals Inc..
David Cantu, PhD (Sunovion Pharmaceuticals Inc.)	Dr. Cantu has received personal compensation for serving as an employee of Sunovion Pharmaceuticals Inc..
Hailong Cheng	No disclosure on file
	No disclosure on file